Business
Admittance to trading on the OTCQB Venture Market
Admittance to trading on the OTCQB Venture Market.
About this update from Genflow Biosciences Plc
[{"type":"text","content":"\n\n \nGenflow Biosciences Plc\n \n(\"Genflow\" or \"the Company\")\n \nAnti-Ageing Company, Genflow Biosciences, Announces Listing on OTCQB Venture Market\nin addition to its LSE Main Market Listing\n \nGenflow has 3 Gene Therapies in Development Seeking to Treat NASH and Werner Syndrome\n \nGenflow Biosciences Plc (\"Genflow\" or \"the Company\") is pleased to announce that, after a successful application process, its Ordinary Shares (\"Ordinary Shares\") begin trading on the OTCQB Venture Market in the United States (\"US\") today under the symbol GENFF. Genflow will continue to trade on the London Stock Exchange (\"LSE\") Main Market under the symbol GENF, and, importantly, the onboarding to this additional U.S. securities trading platform does not involve any capital raise. The new U.S. trading facility expands access to a broader pool of investors and enables investors in the United States to trade during U.S. trading hours and in U.S. dollars. \n \nEric Leire, CEO of Genflow, expressed his excitement about this significant achievement, stating, \"We are thrilled to announce that Genflow Biosciences has been admitted to trading on the OTCQB Venture Market in the United States. This move not only expands our reach to a larger investor base and has the potential to enhance liquidity for our shares, but also reinforces our unwavering commitment to our primary listing on the prestigious London Stock Exchange.\"\n \nTamara Joseph, Chair of the Board, also expressed her enthusiasm on behalf of the Board of Directors, saying, \"Genflow is developing gene therapies that could address an important source of many global illnesses: aging. As the Company moves into Phase I/II clinical trials to treat potentially the orphan condition Werner Syndrome, which causes premature aging, and NASH, a liver disease that affects an estimated 35 million people around the world, it is the right time to retain our London Stock Exchange listing while adding easier access for US investors.\"\n \nFurther information on Genflow's application and the OTCQB market is below:\n \nAs a Foreign Private Issuer, Genflow's admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies. This includes fulfilling the ...